Literature DB >> 3040245

Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.

C G Girón, A Ordónez, J I Jalón, M G Barón.   

Abstract

Thirty-two evaluable patients with stage III non-small cell lung cancer were treated with the combination of ifosfamide (4 g/m2), with uroprotective mesna, mitomycin (6 mg/m2), and cisplatin (100 mg/m2). The overall response rate was 68.8% (complete response rate, 21.9%; partial response rate, 46.9%). Toxicity was moderate and manageable. Based on the response rate observed, this three-drug combination could be considered for future randomized phase III trials against non-small cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3040245

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  6 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.

Authors:  R Honda; A Fujita; Y Inoue; M Asakawa; A Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Ifosfamide, cisplatin, vinblastine combination chemotherapy in the treatment of advanced non-small-cell lung cancer.

Authors:  H Saito; K Shimokata; M Yamamoto; H Saka; S Sakai; H Kawachi; H Saito
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer.

Authors:  D C Currie; D W Miles; J S Drake; R Rudd; S G Spiro; H M Earl; P G Harper; J S Tobias; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.

Authors:  M H Cullen; R Joshi; A D Chetiyawardana; C M Woodroffe
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

6.  Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.

Authors:  A Ardizzoni; G F Addamo; E Baldini; U Borghini; L Portalone; F De Marinis; R Lionetto; P F Conte; P Bruzzi; M C Pennucci
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.